Dr. Nicholas P. Taylor

Gynecologic Oncology | Oncology | Obstetrics and Gynecology
1021 Park Ave, 
Quakertown, PA 
Offers Telehealth
1021 Park Ave, 
Quakertown, PA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Nicholas Taylor is a Gynecologic Oncologist and an Oncologist in Quakertown, Pennsylvania. Dr. Taylor is rated as an Experienced provider by MediFind in the treatment of Liposarcoma. His top areas of expertise are Vulvar Cancer, Endometrial Cancer, Endometrial Stromal Sarcoma, Oophorectomy, and Hysterectomy.

His clinical research consists of co-authoring 10 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Gynecologic Oncology
Oncology
Obstetrics and Gynecology
Licenses
Obstetrics & Gynecology in NJ
Hospital Affiliations
St Luke's Hospital Bethlehem
St Lukes Quakertown Hospital
St Luke's Warren Hospital
St Luke's Hospital - Anderson Campus
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

ST LUKES PHYSICIAN GROUP INC
1021 Park Ave, Quakertown, PA 18951
Other Locations
ST LUKES PHYSICIAN GROUP INC
700 Lawn Ave, Sellersville, PA 18960
ST LUKES PHYSICIAN GROUP INC
701 Ostrum St, Fountain Hill, PA 18015
ST LUKES PHYSICIAN GROUP INC
3000 St Lukes Dr, Quakertown, PA 18951
ST LUKES PHYSICIAN GROUP INC
1736 W Hamilton St, Allentown, PA 18104
ST LUKES PHYSICIAN GROUP INC
142 Clemens Rd, Harleysville, PA 19438

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer
A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 02, 2025
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Atezolizumab, Bevacizumab, Pegylated liposomal doxorubicin hydrochloride
Study Phase: Phase 2/Phase 3
A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 01, 2025
Intervention Type: Drug, Procedure, Other
Study Drugs: Carboplatin, Cediranib Maleate, Gemcitabine, Gemcitabine Hydrochloride, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride
Study Phase: Phase 3
A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
Enrollment Status: Active_not_recruiting
Publish Date: December 01, 2025
Intervention Type: Procedure, Drug, Other
Study Drugs: Cediranib, Cediranib Maleate, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride, Topotecan, Topotecan Hydrochloride
Study Phase: Phase 2/Phase 3
Phase II Randomized Trial of Nivolumab With or Without Ipilimumab in Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Phase II Randomized Trial of Nivolumab With or Without Ipilimumab in Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Enrollment Status: Completed
Publish Date: August 29, 2025
Intervention Type: Biological
Study Phase: Phase 2
Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated With Initial Radical Hysterectomy and Pelvic Lymphadenectomy (NCT #01101451)
Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated With Initial Radical Hysterectomy and Pelvic Lymphadenectomy (NCT #01101451)
Enrollment Status: Completed
Publish Date: May 23, 2025
Intervention Type: Other, Radiation, Drug
Study Drug: Cisplatin
Study Phase: Phase 3
A Randomized, Controlled, Double-Arm, Double-Blind, Multi-Center Study of Ofranergene Obadenovec (VB-111) Combined With Paclitaxel vs. Paclitaxel Combined With Placebo for the Treatment of Recurrent Platinum-Resistant Ovarian Cancer
A Randomized, Controlled, Double-Arm, Double-Blind, Multi-Center Study of Ofranergene Obadenovec (VB-111) Combined With Paclitaxel vs. Paclitaxel Combined With Placebo for the Treatment of Recurrent Platinum-Resistant Ovarian Cancer
Enrollment Status: Completed
Publish Date: January 10, 2023
Intervention Type: Drug
Study Drugs: VB-111, Paclitaxel
Study Phase: Phase 3
A Phase III Trial of Adjuvant Chemotherapy Following Chemoradiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: The OUTBACK Trial
A Phase III Trial of Adjuvant Chemotherapy Following Chemoradiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: The OUTBACK Trial
Enrollment Status: Completed
Publish Date: November 07, 2022
Intervention Type: Other, Drug, Radiation
Study Drugs: Carboplatin, Cisplatin, Paclitaxel
Study Phase: Phase 3
Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Solid Tumors
Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Solid Tumors
Enrollment Status: Completed
Publish Date: September 01, 2022
Intervention Type: Other
View 7 Less Clinical Trials

10 Total Publications

Case report and review of the literature regarding management of primary uterine primitive neuroectodermal tumors (PNET).
Case report and review of the literature regarding management of primary uterine primitive neuroectodermal tumors (PNET).
Journal: Gynecologic oncology reports
Published: March 20, 2025
Similar Doctors
Distinguished in Liposarcoma
Dr. Margaret Von-Mehren
Oncology | Transplant Surgery
Distinguished in Liposarcoma
Dr. Margaret Von-Mehren
Oncology | Transplant Surgery

Temple Faculty Practice Plan Inc

3401 N Broad St, 
Philadelphia, PA 
 (31.7 miles away)
215-707-5030
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Margaret Von-Mehren is an Oncologist and a Transplant Surgeon in Philadelphia, Pennsylvania. Dr. Von-Mehren is rated as a Distinguished provider by MediFind in the treatment of Liposarcoma. Her top areas of expertise are Gastrointestinal Stromal Tumor, Undifferentiated Pleomorphic Sarcoma, Mesenchymoma, and Retroperitoneal Liposarcoma.

Distinguished in Liposarcoma
Dr. Lee Hartner
Hematology | Oncology
Distinguished in Liposarcoma
Dr. Lee Hartner
Hematology | Oncology

Abramson Cancer Center Radnor

145 King Of Prussia Road, Floor 2, Suite 200 North, 
Radnor, PA 
 (27.5 miles away)
800-789-7366
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Lee Hartner is a Hematologist and an Oncologist in Radnor, Pennsylvania. Dr. Hartner is rated as a Distinguished provider by MediFind in the treatment of Liposarcoma. His top areas of expertise are Adult Soft Tissue Sarcoma, Retroperitoneal Liposarcoma, Liposarcoma, Gastrostomy, and Endoscopy. Dr. Hartner is currently accepting new patients.

Distinguished in Liposarcoma
Dr. Atrayee Basu-Mallick
Hematology Oncology | Oncology
Distinguished in Liposarcoma
Dr. Atrayee Basu-Mallick
Hematology Oncology | Oncology

Jefferson University Physicians

111 S 11th St, 
Philadelphia, PA 
 (35.2 miles away)
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Atrayee Basu-Mallick is a Hematologist Oncology specialist and an Oncologist in Philadelphia, Pennsylvania. Dr. Basu-Mallick is rated as a Distinguished provider by MediFind in the treatment of Liposarcoma. Her top areas of expertise are Bone Tumor, Colorectal Cancer, Mesenchymoma, Undifferentiated Pleomorphic Sarcoma, and Pancreaticoduodenectomy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Taylor's expertise for a condition
ConditionClose
    View All 7 Distinguished Conditions
    View All 15 Advanced Conditions
    View All 25 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile